| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Department of Pathology, Weill Medical College of Cornell University, New York, NY.
Correspondence to Rosemary Kraemer, PhD, Weill Medical College of Cornell University, Dept of Pathology, Room A631, 1300 York Ave, New York, NY 10021. E-mail rtkraeme{at}med.cornell.edu
Apoptosis of neointimal smooth muscle cells is a well-recognized component of the pathogenesis of vascular lesions. In recent studies, we have identified the neurotrophin receptor, p75NTR, as a mediator of apoptosis of neointimal smooth muscle cells. Neurotrophin ligands and p75NTR are selectively expressed in areas of atherosclerotic lesions with increased smooth muscle cell apoptosis and the neurotrophins are potent apoptotic agents for p75NTR-expressing smooth muscle cells in vitro. In the present study, we directly assess the role of p75NTR in lesion development in the flow-restricted carotid artery, a model of murine vascular injury. Ligation of the left carotid artery resulted in a 3- to 4-fold increase in lesion development in p75NTR-null mutant mice as compared with wild-type mice. The increase in lesion size was associated with a 70% decrease in apoptosis of neointimal smooth muscle cells, as assessed by in situ TUNEL analysis. These data suggest that under conditions of flow restriction, p75NTR activation impairs lesion formation by promoting smooth muscle cell apoptosis. These results further implicate p75NTR as an important regulator of smooth muscle cell apoptosis and lesion development after vascular injury.
Key Words: p75 neurotrophin receptor neurotrophins smooth muscle cells apoptosis vascular lesions
This article has been cited by other articles:
![]() |
Y. Wei, A. T. Whaley-Connell, J. Habibi, J. Rehmer, N. Rehmer, K. Patel, M. Hayden, V. DeMarco, C. M. Ferrario, J. A. Ibdah, et al. Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation Hypertension, February 1, 2009; 53(2): 158 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Caporali and C. Emanueli Cardiovascular Actions of Neurotrophins Physiol Rev, January 1, 2009; 89(1): 279 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xu, C. V. Remillard, B. D. Sachs, A. Makino, O. Platoshyn, W. Yao, W. H. Dillmann, K. Akassoglou, and J. X.-J. Yuan p75 neurotrophin receptor regulates agonist-induced pulmonary vasoconstriction Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1529 - H1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Sachs, G. S. Baillie, J. R. McCall, M. A. Passino, C. Schachtrup, D. A. Wallace, A. J. Dunlop, K. F. MacKenzie, E. Klussmann, M. J. Lynch, et al. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway J. Cell Biol., July 30, 2007; 177(6): 1119 - 1132. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Korshunov, A. M. Mohan, M. A. Georger, and B. C. Berk Axl, A Receptor Tyrosine Kinase, Mediates Flow-Induced Vascular Remodeling Circ. Res., June 9, 2006; 98(11): 1446 - 1452. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |